Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388296 | 1.00 | P4HB (0.68) | P4HBNR1H4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL9390190 | 0.94 | P4HB (0.71) | P4HBNR1H4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL9390191 | 0.94 | P4HB (0.71) | P4HBNR1H4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL31298979 | 0.91 | MAOB (0.72) | P4HBCYP1B1MAOAMAOBBCHE | |
| SCHEMBL2992884 | 0.89 | P4HB (0.82) | P4HBNR1H4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2992887 | 0.89 | P4HB (0.82) | P4HBNR1H4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL25199667 | 0.86 | CYP1B1 (0.69) | P4HBCYP1A1CYP1A2CYP1B1MAOA | |
| SCHEMBL31233274 | 0.86 | CYP1B1 (0.69) | P4HBCYP1A1CYP1A2CYP1B1MAOA | |
| SCHEMBL30384568 | 0.86 | CYP1B1 (0.69) | P4HBCYP1A1CYP1A2CYP1B1MAOA | |
| SCHEMBL8829843 | 0.86 | CYP1B1 (0.69) | P4HBCYP1A1CYP1A2CYP1B1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6122623-A | — | — | None | — | — | JP | disclosed |
| JP-9309860-A | — | — | None | — | — | JP | disclosed |
| CN-116375695-B | Probe based on flavonoid compound and preparation method and application thereof | 兰州大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-116375695-A | Probe based on flavonoid compound and preparation method and application thereof | 兰州大学 | 2023-07-04 | — | — | CN | disclosed |
| US-8450377-B2 | 1-adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450377-B2 | 1-adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450377-B2 | 1-adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L (US) | 2011-12-29 | — | — | US | disclosed |
| US-20090281196-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L | 2009-11-12 | — | — | US | disclosed |
| US-7563789-B2 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA LONG | 2009-07-21 | — | — | US | disclosed |
| US-7563789-B2 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA LONG | 2009-07-21 | — | — | US | disclosed |
| US-7563789-B2 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA LONG | 2009-07-21 | — | — | US | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20060189580-A1 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L | 2006-08-24 | — | — | US | disclosed |
| US-20050065152-A1 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2005-03-24 | — | — | US | disclosed |
| US-6864264-B1 | 1-adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2005-03-08 | — | — | US | disclosed |
| JP-H09309860-A | CHALCONE COMPOUND AND ANTITUMOR AGENT | MINOFUAAGEN SEIYAKU HONPO:GOUSHI | 1997-12-02 | — | — | JP | disclosed |
| JP-H06122623-A | ANTINEOPLASTIC AGENT | MINOFUAAGEN SEIYAKU HONPO:GOUSHI | 1994-05-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065152-A1 | 1-Adamantyl chalcones for the treatment of proliferative disorders | BRCA1, CYP19A1, HSD17B11 | P4HB 1437/4885NR1H4 352/4885CYP1A1 265/4885 |
| US-20060189580-A1 | 1-Adamantyl chalcones for the treatment of proliferative disorders | BRCA1, CYP19A1, HSD17B11 | P4HB 1437/4885NR1H4 352/4885CYP1A1 265/4885 |
| US-20090281196-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRCA1, CYP19A1, HSD17B11 | P4HB 1437/4885NR1H4 352/4885CYP1A1 265/4885 |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRCA1, CYP19A1, HSD17B11 | P4HB 1437/4885NR1H4 352/4885CYP1A1 265/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | P4HB 3618/4885NR1H4 3502/4885CYP1A1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.